December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Iris Pigmentation Changes Following Treatment With Travoprost Or Latanoprost In Patients With Open-angle Glaucoma Or Ocular Hypertension
Author Affiliations & Notes
  • HI Schenker
    Rochester Ophthalmological Group Rochester NY
  • L Williams
    Alcon Research Ltd Fort Worth TX
  • SM Goode
    Advanced Glaucoma Diagnostics/Treatment Fort Worth TX
  • RD Gross
    Children's Eye Specialists Arlington TX
  • JA Mathis
    Wedgwood Optometry Associates Fort Worth TX
  • S Mallick
    Alcon Research Ltd Fort Worth TX
  • JE Dickerson
    Alcon Research Ltd Fort Worth TX
  • R Andrew
    Alcon Research Ltd Fort Worth TX
  • L Silver
    Alcon Research Ltd Fort Worth TX
  • T Landry
    Alcon Research Ltd Fort Worth TX
  • Footnotes
    Commercial Relationships    H.I. Schenker, Alcon Research, Ltd. F; L. Williams, Alcon Research, Ltd. E; S.M. Goode, Alcon Research, Ltd. C; R.D. Gross, Alcon Research, Ltd. C; J.A. Mathis, Alcon Research, Ltd. C; S. Mallick, Alcon Research, Ltd. E; J.E. Dickerson, Alcon Research, Ltd. E; R. Andrew, Alcon Research, Ltd. E; L. Silver, Alcon Research, Ltd. E; T. Landry, Alcon Research, Ltd. E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3431. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      HI Schenker, L Williams, SM Goode, RD Gross, JA Mathis, S Mallick, JE Dickerson, R Andrew, L Silver, T Landry; Iris Pigmentation Changes Following Treatment With Travoprost Or Latanoprost In Patients With Open-angle Glaucoma Or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3431.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the incidence and time of onset of iris pigmentation changes following treatment of eyes with the ocular hypotensive prostaglandin analogs, Travoprost and Latanoprost. Methods: 1,679 patients enrolled in 4 phase III clinical trials for Travoprost were treated with either Travoprost 0.0015%, Travoprost 0.004% or Latanoprost 0.005%. These patients were followed for changes in iris pigmentation. Close-up macro POLAROID photographs were taken of the irides at baseline (pre-therapy), and, depending on the study, at periodic intervals for up to one year following the start of treatment. All photographs for a given patient were taken with similar lighting conditions and at the same camera exposure setting. Iris photos taken at study visits for each patient were subjectively compared with photos of the patient's irides at baseline by two independent readers. If the two readers did not agree, the photographs were evaluated by a third reader. The study was masked to the reader panel. Confirmation of a pigmentation change required agreement by 2 of the 3 readers. All patients with confirmed iris color changes were notified and asked to participate in a follow-up study in which the irides were photographed periodically for an additional 2 years. Results: Pigmentation changes were documented for 21 of 739 (2.8%) patients receiving Travoprost 0.0015%, 20 of 744 (2.7%) patients receiving Travoprost 0.004%, and 10 of 196 (5.1%) patients receiving Latanoprost. The incidence of pigmentation change varied with the baseline iris color classification. The highest incidence was found for the hazel or green (7-9%) iris classifications while the lowest incidence was found in brown (3%) or blue (<1%) irides. Of the patients who exhibited an iris pigmentation change, 37 (72.5%) were first noted at ≥ 6 months following start of therapy. Conclusion: Iris pigmentation change was observed in approximately 3% of patients receiving Travoprost (0.0015% or 0.004%) compared to approximately 5% of patients receiving Latanoprost 0.005%.

Keywords: 447 iris 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.